Overall, defining how Aβ and p-tau pathology, genetic and other risk factors for AD, and deterioration of cell-cell interactions interplay to drive myelin dysfunction may reveal novel targets for therapeutic development for AD. The gene discussed is MAPT; the disease is Alzheimer disease.